Fellowship · Orlando, FL
Sponsored by AdventHealth Florida
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
JAMA oncology · 2021 · 260 citations · Tarik Mekhail
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Cancer discovery · 2021 · 192 citations · Tarik Mekhail
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Nature medicine · 2022 · 158 citations · Tarik Mekhail
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024 · 56 citations · Tarik Mekhail
Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Antimicrobial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections.
Transplantation and cellular therapy · 2021 · 35 citations · Rushang Patel
Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations.
Current oncology (Toronto, Ont.) · 2025 · 7 citations · Mariem Galuia
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.
JTO clinical and research reports · 2022 · 31 citations · Tarik Mekhail
Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions.
Journal of cellular and molecular medicine · 2021 · 22 citations · Brian Parkin